PORTLAND, Ore.--(BUSINESS WIRE)--AVI BioPharma, Inc. (Nasdaq:AVII), today announced publication of preclinical results from studies carried out by an international team of researchers showing the ability of NEUGENE® antisense to inhibit multiple strains of influenza A virus.
